New editorial in this weeks Journal of the America
Post# of 72445
(Total Views: 763)
Posted On: 09/23/2020 8:52:12 PM
New editorial in this weeks Journal of the American Medical Association reviews Remdesivir and its clinical trials. The article highlights the shortcomings of all the studies and the uncertainty of Remdesivir's clinical benefit as well as the need for scientific rigorous studies.
The medical community will receive an effective Covid19 antiviral which is safe and effective with enthusiasm.
The timing for the Brilacidin trials could not be better.
https://jamanetwork.com/journals/jama/fullarticle/2769870
GLTA Farrell
"The report by Spinner et al in this issue of JAMA provides important new data on the potential efficacy of remdesivir in patients with moderate COVID-19 and suggests modest clinical benefit for the 5-day course compared with standard care, although, as the authors acknowledge, the clinical importance of this finding is uncertain. Some of the variation in results from the RCTs of remdesivir could be due to differences in study design. Nonetheless, in aggregate, important questions remain regarding the efficacy of remdesivir. First, the optimal patient population is unclear. Second, the optimal duration of therapy is unclear. Third, the effect on discrete clinical outcomes is unclear. Fourth, the relative effect of the drug if given in the presence of dexamethasone or other corticosteroids is unclear. Some of the RCT findings suggest remdesivir could improve recovery for many millions of individuals around the world who may be hospitalized with COVID-19. However, the costs to produce and distribute remdesivir at such scale are considerable, and, most importantly, whether remdesivir offers incremental benefit over corticosteroids, which are widely available and inexpensive, is unknown. It therefore seems prudent to urgently conduct further evaluations of remdesivir in large-scale RCTs designed to address the residual uncertainties and inform optimal use."
The medical community will receive an effective Covid19 antiviral which is safe and effective with enthusiasm.
The timing for the Brilacidin trials could not be better.
https://jamanetwork.com/journals/jama/fullarticle/2769870
GLTA Farrell
"The report by Spinner et al in this issue of JAMA provides important new data on the potential efficacy of remdesivir in patients with moderate COVID-19 and suggests modest clinical benefit for the 5-day course compared with standard care, although, as the authors acknowledge, the clinical importance of this finding is uncertain. Some of the variation in results from the RCTs of remdesivir could be due to differences in study design. Nonetheless, in aggregate, important questions remain regarding the efficacy of remdesivir. First, the optimal patient population is unclear. Second, the optimal duration of therapy is unclear. Third, the effect on discrete clinical outcomes is unclear. Fourth, the relative effect of the drug if given in the presence of dexamethasone or other corticosteroids is unclear. Some of the RCT findings suggest remdesivir could improve recovery for many millions of individuals around the world who may be hospitalized with COVID-19. However, the costs to produce and distribute remdesivir at such scale are considerable, and, most importantly, whether remdesivir offers incremental benefit over corticosteroids, which are widely available and inexpensive, is unknown. It therefore seems prudent to urgently conduct further evaluations of remdesivir in large-scale RCTs designed to address the residual uncertainties and inform optimal use."
(3)
(1)